Bakay, U. and İzci Duran, T. (2025) “Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a Single-Center Cohort”, Archives of Rheumatology, 40(4), pp. 465–473. doi: 10.5152/ArchRheumatol.2025.11098.